Literature DB >> 10069460

Characterization of cytochrome P450 expression in human oesophageal mucosa.

M Lechevrel1, A G Casson, C R Wolf, L J Hardie, M B Flinterman, R Montesano, C P Wild.   

Abstract

The expression of cytochrome (CYP) P450 enzymes in human oesophageal mucosa was investigated in a total of 25 histologically non-neoplastic surgical tissue specimens by using specific antibodies in immunoblots and by RT-PCR mRNA analysis. The presence of CYP1A, 2E1, 3A and 4A enzymes was demonstrated by both techniques; CYP2A reactive protein was also detected by immunoblot. The presence of CYP4B1 mRNA was established but no specific antibody was available for detection of the corresponding protein by immunoblot. CYP2B6/7 mRNA was not detected in any sample. The mRNA transcripts for CYP1A1, 2E1, 4A11 and 4B1 were consistently detected in the majority of samples (>84%), whereas CYP1A2 mRNA was only detected in 11 of 19 specimens examined. An RT-PCR method to differentiate CYP3A4 and 3A5 mRNA was developed. This demonstrated CYP3A5 mRNA expression in all samples tested, whereas CYP3A4 mRNA was not detectable, suggesting that CYP3A5 is the major CYP3A protein in human oesophagus. There were significant interindividual variations in the amount of proteins, ranging from 8-fold for CYP4A to 43-fold for CYP2E1. For each patient, data on exposure to risk factors for oesophageal cancer were available, including tobacco smoke, alcohol, gastro-oesophageal reflux and hot beverage consumption. None of these risk factors or other patient characteristics (age, sex, tumour location and tumour stage) were correlated with the protein level of the individual CYP enzymes as determined by quantitation of immunoblot staining. However, the small series of samples precludes any strong conclusion concerning the lack of such correlations. There were no differences between squamous cell carcinomas and adenocarcinomas in either the qualitative or quantitative expression of the CYP enzymes. These data demonstrate that a range of CYP enzymes are expressed in human oesophageal mucosa and indicate that this tissue has the capacity to activate chemical carcinogens to reactive DNA binding metabolites.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069460     DOI: 10.1093/carcin/20.2.243

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  15 in total

Review 1.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

2.  Phase I/II enzyme gene polymorphisms and esophageal cancer risk: a meta-analysis of the literature.

Authors:  Chun-Xia Yang; Keitaro Matsuo; Zhi-Ming Wang; Kazuo Tajima
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

Review 3.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Cytochrome P450 levels are altered in patients with esophageal squamous-cell carcinoma.

Authors:  I Bergheim; E Wolfgarten; E Bollschweiler; A-H Hölscher; C Bode; A Parlesak
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

6.  Aryl hydrocarbon receptor expression is associated with a family history of upper gastrointestinal tract cancer in a high-risk population exposed to aromatic hydrocarbons.

Authors:  Mark J Roth; Wen-Qiang Wei; Jessica Baer; Christian C Abnet; Guo-Qing Wang; Lawrence R Sternberg; Andrew C Warner; Laura Lee Johnson; Ning Lu; Carol A Giffen; Sanford M Dawsey; You-Lin Qiao; James Cherry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-08-18       Impact factor: 4.254

7.  Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.

Authors:  Monica Gandhi; Leslie Z Benet; Peter Bacchetti; Ann Kalinowski; Kathryn Anastos; Alan R Wolfe; Mary Young; Mardge Cohen; Howard Minkoff; Stephen J Gange; Ruth M Greenblatt
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-15       Impact factor: 3.731

8.  Activities of human recombinant cytochrome P450 isoforms and human hepatic microsomes for the hydroxylation ofAlternaria toxins.

Authors:  E Pfeiffer; B Burkhardt; M Altemöller; J Podlech; M Metzler
Journal:  Mycotoxin Res       Date:  2008-09       Impact factor: 3.833

9.  Association between CYP1A1 polymorphisms and esophageal cancer: a meta-analysis.

Authors:  Fang-Fang Shen; Fu-You Zhou; Qi-Si Xue; Ying Pan; Lu Zheng; Hua Zhang; Li-Dong Wang; Hou-Feng Zheng
Journal:  Mol Biol Rep       Date:  2013-09-25       Impact factor: 2.316

10.  Impact of phase I metabolism on uptake, oxidative stress and genotoxicity of the emerging mycotoxin alternariol and its monomethyl ether in esophageal cells.

Authors:  Christine Tiessen; Doris Ellmer; Hannes Mikula; Gudrun Pahlke; Benedikt Warth; Helge Gehrke; Kristin Zimmermann; Elke Heiss; Johannes Fröhlich; Doris Marko
Journal:  Arch Toxicol       Date:  2016-07-15       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.